Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab sequential chemoradiotherapy as neoadjuvant treatment for esophageal squamous cell carcinoma
ChiCTR2000034311Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Postoperative pathological complete remission rate. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000034311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034311.